Table 2. Antihypertensive treatment at baseline.
| Total Cohort (n = 938) |
Age < 65 years (n = 748) |
Age ≥ 65 years (n = 190) |
P-values | |
| Data are presented as n (%). ACE: angiotensin-converting enzyme; ARB: angiotensin-receptor blockers. | ||||
| Antihypertensive treatment | 685 (73.0%) | 522 (69.8%) | 163 (85.8%) | < 0.001 |
| Neutral antihypertensive treatment | 774 (82.5%) | 647 (86.5%) | 127 (66.8%) | < 0.001 |
| Calcium channel blockers | 502 (53.6%) | 397 (53.1%) | 105 (55.3%) | 0.589 |
| Alpha blockers | 289 (30.8%) | 213 (28.5%) | 76 (40.0%) | 0.002 |
| Centrally acting drugs | 165 (17.6%) | 112 (15.0%) | 53 (27.9%) | < 0.001 |
| Loop diuretics | 31 (3.3%) | 17 (2.3%) | 14 (7.4%) | < 0.001 |
| ACE inhibitors | 39 (4.2%) | 25 (3.3%) | 14 (7.4%) | 0.013 |
| ARB | 61 (6.5%) | 34 (4.5%) | 27 (14.2%) | < 0.001 |
| Beta blockers | 76 (8.1%) | 48 (6.4%) | 28 (14.7%) | < 0.001 |
| Thiazide diuretics | 58 (6.2%) | 37 (4.9%) | 21 (11.1%) | 0.002 |
| Spironolactone | 19 (2.0%) | 13 (1.7%) | 6 (3.2%) | 0.215 |
| Amiloride | 6 (0.6%) | 3 (0.4%) | 3 (1.6%) | 0.069 |